Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS

被引:101
作者
Rudick, Richard A. [1 ]
Lee, Jar-Chi [2 ]
Nakamura, Kunio [3 ]
Fisher, Elizabeth [3 ]
机构
[1] Cleveland Clin, Mellen Ctr MS Treatment & Res U10, Neurol Inst, Cleveland, OH USA
[2] Cleveland Clin, Quantitat Hlth Sci Wb4, Lerner Res Inst, Cleveland, OH USA
[3] Cleveland Clin, Dept Biomed Engn ND20, Lerner Res Inst, Cleveland, OH USA
基金
美国国家卫生研究院;
关键词
Multiple scleroses; Brain atrophy; Gray matter; Disability; Magnetic resonance imaging; REMITTING MULTIPLE-SCLEROSIS; BRAIN ATROPHY; WHITE-MATTER; CLINICAL-RELEVANCE; CORTICAL-LESIONS; CEREBRAL ATROPHY; VOLUME CHANGES; GREY; TRIAL; MRI;
D O I
10.1016/j.jns.2008.11.018
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Gray matter (GM) pathology is an important component of the multiple sclerosis (MS) disease process. Accelerated gray matter atrophy has been observed in MS patients, but its relationship to neurological disability is not defined. This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression. Methods: Patients with MS and Clinically Isolated Syndromes (CIS), and age- and gender-matched healthy controls were entered into an observational protocol. Baseline brain parenchymal fraction (BPF), GM fraction, and WM fraction, and change over 4 years were correlated with sustained disability progression over the entire study duration. Disability progression was measured using the Multiple Sclerosis Functional Composite (MSFC) and the Expanded Disability Status Scale (EDSS). Results: Seventy MS and CIS patients and 17 HCs were studied for an average of 6.6 years (range, 3.6-7.8 years). At the final visit, 7 patients were classified as CIS, 36 as relapsing-remitting MS (RRMS), and 27 as secondary progressive MS (SPMS). Baseline whole brain, GM, and WM atrophy predicted EDSS >6.0 at the last study visit. Twenty-one (33%) patients worsened using the EDSS to define disability progression; 29 (46%) worsened using MSFC to define disability progression. Patients with MSFC progression had significantly higher GM atrophy rates compared with patients who were stable on MSFC. White matter atrophy was similar in patients with and without disability progression. Atrophy rates were not different in patients with or without disability progression defined using EDSS. Conclusions: Whole brain, GM, and WM atrophy predicted MS disability progression observed over the next 6.6 years. Gray matter atrophy rates over 4 years correlated with disability progression measured with the MSFC, but not EDSS. This indicates that MSFC defined disability progression is more closely linked to brain atrophy than EDSS defined disability progression, and provides important new insight into the poor correlation between MRI and clinical disability in MS. The findings confirm the clinical relevance of gray matter atrophy in MS. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 35 条
[1]  
ADAMS R, 1961, CHEM PATHOLOGY NERVO, P163
[2]   The measurement and clinical relevance of brain atrophy in multiple sclerosis [J].
Bermel, RA ;
Bakshi, R .
LANCET NEUROLOGY, 2006, 5 (02) :158-170
[3]   Detection of ventricular enlargement in patients at the earliest clinical stage of MS [J].
Brex, PA ;
Jenkins, R ;
Fox, NC ;
Crum, WR ;
O'Riordan, JI ;
Plant, GT ;
Miller, DH .
NEUROLOGY, 2000, 54 (08) :1689-1691
[4]   Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis [J].
Chard, DT ;
Griffin, CM ;
Rashid, W ;
Davies, GR ;
Altmann, DR ;
Kapoor, R ;
Barker, GJ ;
Thompson, AJ ;
Miller, DH .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) :387-391
[5]   Brain atrophy in clinically early relapsing-remitting multiple sclerosis [J].
Chard, DT ;
Griffin, CM ;
Parker, GJM ;
Kapoor, R ;
Thompson, AJ ;
Miller, DH .
BRAIN, 2002, 125 :327-337
[6]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[7]   Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes [J].
Dalton, CM ;
Chard, DT ;
Davies, GR ;
Miszkiel, KA ;
Altmann, DR ;
Fernando, K ;
Plant, GT ;
Thompson, AJ ;
Miller, DH .
BRAIN, 2004, 127 :1101-1107
[8]   Disability as an outcome in MS clinical trials [J].
Ebers, G. C. ;
Heigenhauser, L. ;
Daumer, M. ;
Lederer, C. ;
Noseworthy, J. H. .
NEUROLOGY, 2008, 71 (09) :624-631
[9]   Whole brain volume changes in patients with progressive MS treated with cladribine [J].
Filippi, M ;
Rovaris, M ;
Iannucci, G ;
Mennea, S ;
Sormani, MP ;
Comi, G .
NEUROLOGY, 2000, 55 (11) :1714-1718
[10]   Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Filippi, M ;
Rovaris, M ;
Inglese, M ;
Barkhof, F ;
De Stefano, N ;
Smith, S ;
Comi, G .
LANCET, 2004, 364 (9444) :1489-1496